Identification of immunogenic LY6K long peptide encompassing both CD4+ and CD8+ T-cell epitopes and eliciting CD4+ T-cell immunity in patients with malignant disease

OncoImmunology

Volumn 3, Issue 3, 2014, Pages

  Tomita, Yusuke ^a   Yuno, Akira ^a   Tsukamoto, Hirotake ^a   Senju, Satoru ^a   Kuroda, Yasuhiro ^a   Hirayama, Masatoshi ^a   Imamura, Yuya ^a   Yatsuda, Junji ^a   Sayem, Mohammad Abu ^a,b   Irie, Atsushi ^a   Hamada, Akinobu ^c   Jono, Hirofumi ^c   Yoshida, Koji ^d,e   Tsunoda, Takuya ^d,e   Daigo, Yataro ^d,f   Kohrogi, Hirotsugu ^a   Yoshitake, Yoshihiro ^a   Nakamura, Yusuke ^c,g   Shinohara, Masanori ^a   Nishimura, Yasuharu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b MAWLANA BHASHANI SCIENCE AND TECHNOLOGY UNIVERSITY   (Bangladesh)

^c KUMAMOTO UNIVERSITY   (Japan)

^d THE UNIVERSITY OF TOKYO   (Japan)

^e Research and Development Division   (Japan)

^f SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^g UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer testis antigen; Cross presentation; Crosspriming; CTL epitope; Head and neck cancer; Helper T cell epitope; Immunotherapy; Lymphocyte antigen 6 complex locus K; Th1 cells

Indexed keywords

CANCER TESTIS ANTIGEN; EPITOPE; GAMMA INTERFERON; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIGEN 6 COMPLEX K 172 191; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANTIGEN DETECTION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL KILLING; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEAD AND NECK TUMOR; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR CELL; VACCINATION; VERY ELDERLY; YOUNG ADULT;

EID: 84902449799     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28100     Document Type: Article

References (48)

1. Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, et al. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 2007; 67:11601-11; PMID:18089789; http://dx.doi.org/10.1158/0008-5472.CAN-07-3243
2. Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 2007; 98:1803-8; PMID:17784873; http://dx.doi. org/10.1111/j.1349-7006.2007.00603.x
3. Mizukami Y, Kono K, Daigo Y, Takano A, Tsunoda T, Kawaguchi Y, Nakamura Y, Fujii H. Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci 2008; 99:1448-54; PMID:18452554; http://dx.doi. org/10.1111/j.1349-7006.2008.00844.x
4. Suzuki H, Fukuhara M, Yamaura T, Mutoh S, Okabe N, Yaginuma H, Hasegawa T, Yonechi A, Osugi J, Hoshino M, et al. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J Transl Med 2013; 11:97; PMID:23578144; http://dx.doi. org/10.1186/1479-5876-11-97
5. Ishikawa H, Imano M, Shiraishi O, Yasuda A, Peng YF, Shinkai M, Yasuda T, Imamoto H, Shiozaki H. Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer. Gastric Cancer 2014; 17:173-80; PMID:23613128; http://dx.doi.org/10.1007/s10120-013-0258-6
6. Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, Noguchi T, Fujii H, Okinaka K, Fukushima R, et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 2012; 10:141; PMID:22776426; http://dx.doi. org/10.1186/1479-5876-10-141
7. Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, Tsunoda T, Kawaguchi Y, Nakamura Y, Fujii H. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009; 100:1502-9; PMID:19459850; http://dx.doi. org/10.1111/j.1349-7006.2009.01200.x
8. Iwahashi M, Katsuda M, Nakamori M, Nakamura M, Naka T, Ojima T, Iida T, Yamaue H. Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci 2010; 101:2510-7; PMID:20874827; http://dx.doi. org/10.1111/j.1349-7006.2010.01732.x
9. Dobrzanski MJ. Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol 2013; 3:63; PMID:23533029; http://dx.doi.org/10.3389/fonc.2013.00063
10. Church SE, Jensen SM, Antony PA, Restifo NP, Fox BA. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur J Immunol 2014; 44:69-79; PMID:24114780; http://dx.doi.org/10.1002/eji.201343718
11. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 2010; 70:8368-77; PMID:20940398; http://dx.doi. org/10.1158/0008-5472.CAN-10-1322
12. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008; 8:351-60; PMID:18418403; http://dx.doi.org/10.1038/nrc2373
13. Melief CJ. "License to kill" reflects joint action of CD4 and CD8 T cells. Clin Cancer Res 2013; 19:4295-6; PMID:23785048; http://dx.doi. org/10.1158/1078-0432.CCR-13-1432
14. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009; 27:4685-92; PMID:19720923; http://dx.doi.org/10.1200/JCO.2008.20.6789
15. Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res 2011; 17:6847-57; PMID:21918169; http://dx.doi.org/10.1158/1078-0432.CCR-11-1385
16. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361:1838-47; PMID:19890126; http://dx.doi. org/10.1056/NEJMoa0810097
17. Tomita Y, Nishimura Y. Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells. Oncoimmunology 2013; 2:e25801; PMID:24327937; http://dx.doi. org/10.4161/onci.25801
18. Tomita Y, Yuno A, Tsukamoto H, Senju S, Yoshimura S, Osawa R, Kuroda Y, Hirayama M, Irie A, Hamada A, et al. Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes:CDCA1-specific CD4+ T-cell immunity in cancer patients. Int J Cancer 2014; 134:352-66; http://dx.doi.org/10.1002/ijc.28376
19. Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, Peters B. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics 2010; 11:568; PMID:21092157; http://dx.doi. org/10.1186/1471-2105-11-568
20. Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, Irie A, Kawahara K, Yatsuda J, Hamada A, et al. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes:KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor. Clin Cancer Res 2013; 19:4508-20; PMID:23714729; http://dx.doi. org/10.1158/1078-0432.CCR-13-0197
21. Saito S, Ota S, Yamada E, Inoko H, Ota M. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens 2000; 56:522-9; PMID:11169242; http://dx.doi. org/10.1034/j.1399-0039.2000.560606.x
22. Mack SJ, Bugawan TL, Moonsamy PV, Erlich JA, Trachtenberg EA, Paik YK, Begovich AB, Saha N, Beck HP, Stoneking M, et al. Evolution of Pacific/Asian populations inferred from HLA class II allele frequency distributions. Tissue Antigens 2000; 55:383-400; PMID:10885559; http://dx.doi. org/10.1034/j.1399-0039.2000.550501.x
23. Harao M, Hirata S, Irie A, Senju S, Nakatsura T, Komori H, Ikuta Y, Yokomine K, Imai K, Inoue M, et al. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Int J Cancer 2008; 123:2616-25; PMID:18770861; http://dx.doi.org/10.1002/ijc.23823
24. Tomita Y, Harao M, Senju S, Imai K, Hirata S, Irie A, Inoue M, Hayashida Y, Yoshimoto K, Shiraishi K, et al. Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells. Cancer Sci 2011; 102:71-8; PMID:21087352; http://dx.doi. org/10.1111/j.1349-7006.2010.01780.x
25. Casazza JP, Betts MR, Price DA, Precopio ML, Ruff LE, Brenchley JM, Hill BJ, Roederer M, Douek DC, Koup RA. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med 2006; 203:2865-77; PMID:17158960; http://dx.doi.org/10.1084/jem.20052246
26. Attig S, Hennenlotter J, Pawelec G, Klein G, Koch SD, Pircher H, Feyerabend S, Wernet D, Stenzl A, Rammensee HG, et al. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 2009; 69:8412-9; PMID:19843860; http://dx.doi.org/10.1158/0008-5472.CAN-09-0852
27. Widenmeyer M, Griesemann H, Stevanović S, Feyerabend S, Klein R, Attig S, Hennenlotter J, Wernet D, Kuprash DV, Sazykin AY, et al. Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients. Int J Cancer 2012; 131:140-9; PMID:21858810; http://dx.doi.org/10.1002/ijc.26365
28. Martorelli D, Muraro E, Merlo A, Turrini R, Rosato A, Dolcetti R. Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer. Int Rev Immunol 2010; 29:371-402; PMID:20635880; http://dx.doi.org/10.3109/08830185.2010.489658
29. Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res 2011; 71:1253-62; PMID:21216894; http://dx.doi.org/10.1158/0008-5472.CAN-10-2693
30. Ribas A, Timmerman JM, Butterfield LH, Economou JS. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 2003; 24:58-61; PMID:12547500; http://dx.doi.org/10.1016/S1471-4906(02)00029-7
31. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358:2698-703; PMID:18565862; http://dx.doi.org/10.1056/NEJMoa0800251
32. Castellino F, Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol 2006; 24:519-40; PMID:16551258; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115825
33. Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, Schreibelt G, Mus R, De Wilt JH, Haanen JB, et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 2013; 73:19-29; PMID:23087058; http://dx.doi. org/10.1158/0008-5472.CAN-12-1127
34. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi. org/10.1038/nrc3239
35. Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A, et al. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 2012; 30:1835-41; PMID:22529253; http://dx.doi.org/10.1200/JCO.2011.40.2271
36. Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, Benhamouda N, Cazes A, Le Pimpec-Barthes F, Gaugler B, et al. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res 2012; 18:2943-53; PMID:22407833; http://dx.doi. org/10.1158/1078-0432.CCR-11-3185
37. Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin Cancer Res 2011; 17:4568-80; PMID:21586625; http://dx.doi. org/10.1158/1078-0432.CCR-11-0184
38. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
39. Ding ZC, Zhou G. Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol 2012; 2012:890178; PMID:22400040; http://dx.doi. org/10.1155/2012/890178
40. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18:1254-61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883
41. Tomita Y, Imai K, Senju S, Irie A, Inoue M, Hayashida Y, Shiraishi K, Mori T, Daigo Y, Tsunoda T, et al. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells. Cancer Sci 2011; 102:697-705; PMID:21231984; http://dx.doi. org/10.1111/j.1349-7006.2011.01865.x
42. Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T, Kuzushima K. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells. Cancer Sci 2008; 99:1633-42; PMID:18754877; http://dx.doi. org/10.1111/j.1349-7006.2008.00852.x
43. Ramduth D, Day CL, Thobakgale CF, Mkhwanazi NP, de Pierres C, Reddy S, van der Stok M, Mncube Z, Nair K, Moodley ES, et al. Immunodominant HIV-1 Cd4+ T cell epitopes in chronic untreated clade C HIV-1 infection. PLoS One 2009; 4:e5013; PMID:19352428; http://dx.doi.org/10.1371/journal. pone.0005013
44. Tabata H, Kanai T, Yoshizumi H, Nishiyama S, Fujimoto S, Matsuda I, Yasukawa M, Matsushita S, Nishimura Y. Characterization of self-glutamic acid decarboxylase 65-reactive CD4+ T-cell clones established from Japanese patients with insulin-dependent diabetes mellitus. Hum Immunol 1998; 59:549-60; PMID:9757911; http://dx.doi.org/10.1016/S0198-8859(98)00050-0
45. Zarour HM, Storkus WJ, Brusic V, Williams E, Kirkwood JM. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res 2000; 60:4946-52; PMID:10987311
46. Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, et al. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res 2008; 14:6487-95; PMID:18927288; http://dx.doi.org/10.1158/1078-0432.CCR-08-1086
47. Jung KO, Khan AM, Tan BY, Hu Y, Simon GG, Nascimento EJ, Lemonnier F, Brusic V, Miotto O, Tan TW, et al. West Nile virus T-cell ligand sequences shared with other flaviviruses: a multitude of variant sequences as potential altered peptide ligands. J Virol 2012; 86:7616-24; PMID:22573867; http://dx.doi. org/10.1128/JVI.00166-12
48. Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, et al. T cell assays and MIATA: the essential minimum for maximum impact. Immunity 2012; 37:1-2; PMID:22840835; http://dx.doi.org/10.1016/j.immuni.2012.07.010